144 related articles for article (PubMed ID: 29997388)
1. Private payer coverage policies for exome sequencing (ES) in pediatric patients: trends over time and analysis of evidence cited.
Douglas MP; Parker SL; Trosman JR; Slavotinek AM; Phillips KA
Genet Med; 2019 Jan; 21(1):152-160. PubMed ID: 29997388
[TBL] [Abstract][Full Text] [Related]
2. Perspectives of US private payers on insurance coverage for pediatric and prenatal exome sequencing: Results of a study from the Program in Prenatal and Pediatric Genomic Sequencing (P3EGS).
Trosman JR; Weldon CB; Slavotinek A; Norton ME; Douglas MP; Phillips KA
Genet Med; 2020 Feb; 22(2):283-291. PubMed ID: 31501586
[TBL] [Abstract][Full Text] [Related]
3. EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS.
Chambers JD; Saret CJ; Anderson JE; Deverka PA; Douglas MP; Phillips KA
Int J Technol Assess Health Care; 2017 Jan; 33(4):534-540. PubMed ID: 29065945
[TBL] [Abstract][Full Text] [Related]
4. US private payers' perspectives on insurance coverage for genome sequencing versus exome sequencing: A study by the Clinical Sequencing Evidence-Generating Research Consortium (CSER).
Phillips KA; Trosman JR; Douglas MP; Gelb BD; Ferket BS; Hindorff LA; Slavotinek AM; Berg JS; Russell HV; Devine B; Greve V; Smith HS
Genet Med; 2022 Jan; 24(1):238-244. PubMed ID: 34906461
[TBL] [Abstract][Full Text] [Related]
5. Variation in Private Payer Coverage of Rheumatoid Arthritis Drugs.
Chambers JD; Wilkinson CL; Anderson JE; Chenoweth MD
J Manag Care Spec Pharm; 2016 Oct; 22(10):1176-81. PubMed ID: 27668566
[TBL] [Abstract][Full Text] [Related]
6. Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage Policies.
Chambers JD; Pope EF; Wilkinson CL; Neumann PJ
J Manag Care Spec Pharm; 2018 Dec; 24(12):1240-1246. PubMed ID: 30479201
[TBL] [Abstract][Full Text] [Related]
7. Evidence Guiding Commercial Payer Coverage Criteria for Total Ankle Arthroplasty.
Kotlier JL; Fathi A; Ong MY; Yazditabar JM; Panoussi EE; Mayfield CK; Petrigliano FA; Liu JN; Peterson AB; Tan EW
Foot Ankle Orthop; 2024 Jan; 9(1):24730114241239310. PubMed ID: 38529013
[TBL] [Abstract][Full Text] [Related]
8. A single center experience with publicly funded clinical exome sequencing for neurodevelopmental disorders or multiple congenital anomalies.
Pode-Shakked B; Barel O; Singer A; Regev M; Poran H; Eliyahu A; Finezilber Y; Segev M; Berkenstadt M; Yonath H; Reznik-Wolf H; Gazit Y; Chorin O; Heimer G; Gabis LV; Tzadok M; Nissenkorn A; Bar-Yosef O; Zohar-Dayan E; Ben-Zeev B; Mor N; Kol N; Nayshool O; Shimshoviz N; Bar-Joseph I; Marek-Yagel D; Javasky E; Einy R; Gal M; Grinshpun-Cohen J; Shohat M; Dominissini D; Raas-Rothschild A; Rechavi G; Pras E; Greenbaum L
Sci Rep; 2021 Sep; 11(1):19099. PubMed ID: 34580403
[TBL] [Abstract][Full Text] [Related]
9. Mapping US commercial payers' coverage policies for medical interventions.
Chambers JD; Chenoweth MD; Neumann PJ
Am J Manag Care; 2016 Sep; 22(9):e323-8. PubMed ID: 27662396
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Exome Sequencing Criteria for Hospital Stewardship and Insurance Authorization at a Pediatric Hospital.
Wittowski CL; Clowes Candadai S; Perrone ME; Gallego DF; Conta JH; Dickerson JA
Arch Pathol Lab Med; 2022 Jan; 146(1):107-111. PubMed ID: 33836053
[TBL] [Abstract][Full Text] [Related]
11. Private payer coverage policies for ApoE-e4 genetic testing.
Arias JJ; Tyler AM; Douglas MP; Phillips KA
Genet Med; 2021 Apr; 23(4):614-620. PubMed ID: 33420342
[TBL] [Abstract][Full Text] [Related]
12. Yield of whole exome sequencing in undiagnosed patients facing insurance coverage barriers to genetic testing.
Reuter CM; Kohler JN; Bonner D; Zastrow D; Fernandez L; Dries A; Marwaha S; Davidson J; Brokamp E; Herzog M; Hong J; Macnamara E; Rosenfeld JA; Schoch K; Spillmann R; ; Loscalzo J; Krier J; Stoler J; Sweetser D; Palmer CGS; Phillips JA; Shashi V; Adams DA; Yang Y; Ashley EA; Fisher PG; Mulvihill JJ; Bernstein JA; Wheeler MT
J Genet Couns; 2019 Dec; 28(6):1107-1118. PubMed ID: 31478310
[TBL] [Abstract][Full Text] [Related]
13. Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling.
Wang G; Beattie MS; Ponce NA; Phillips KA
Genet Med; 2011 Dec; 13(12):1045-50. PubMed ID: 21844812
[TBL] [Abstract][Full Text] [Related]
14. Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 2019.
Douglas MP; Gray SW; Phillips KA
J Natl Compr Canc Netw; 2020 Jul; 18(7):866-872. PubMed ID: 32634780
[TBL] [Abstract][Full Text] [Related]
15. Proband-Only Clinical Exome Sequencing for Neurodevelopmental Disabilities.
Kim SH; Kim B; Lee JS; Kim HD; Choi JR; Lee ST; Kang HC
Pediatr Neurol; 2019 Oct; 99():47-54. PubMed ID: 30952489
[TBL] [Abstract][Full Text] [Related]
16. Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019.
Trosman JR; Douglas MP; Liang SY; Weldon CB; Kurian AW; Kelley RK; Phillips KA
Value Health; 2020 May; 23(5):551-558. PubMed ID: 32389219
[TBL] [Abstract][Full Text] [Related]
17. Private Payer and Medicare Coverage Policies for Use of Circulating Tumor DNA Tests in Cancer Diagnostics and Treatment.
Douglas MP; Ragavan MV; Chen C; Kumar A; Gray SW; Blakely CM; Phillips KA
J Natl Compr Canc Netw; 2023 Jun; 21(6):609-616.e4. PubMed ID: 37308126
[TBL] [Abstract][Full Text] [Related]
18. Long-term economic impacts of exome sequencing for suspected monogenic disorders: diagnosis, management, and reproductive outcomes.
Schofield D; Rynehart L; Shresthra R; White SM; Stark Z
Genet Med; 2019 Nov; 21(11):2586-2593. PubMed ID: 31110331
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders.
Srivastava S; Love-Nichols JA; Dies KA; Ledbetter DH; Martin CL; Chung WK; Firth HV; Frazier T; Hansen RL; Prock L; Brunner H; Hoang N; Scherer SW; Sahin M; Miller DT;
Genet Med; 2019 Nov; 21(11):2413-2421. PubMed ID: 31182824
[TBL] [Abstract][Full Text] [Related]
20. Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature.
Schwarze K; Buchanan J; Taylor JC; Wordsworth S
Genet Med; 2018 Oct; 20(10):1122-1130. PubMed ID: 29446766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
